Phase 1/2 Study in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL 2
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, drug levels, molecular effects, and
clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid
tumors that have a KRAS G12C mutation.